Khoza-Shangase K, Arendse S M
Department of Audiology, School of Human and Community Development, University of the Witwatersrand, Johannesburg, South Africa.
Public Health Action. 2025 Mar 1;15(1):1-3. doi: 10.5588/pha.24.0053. eCollection 2025 Mar.
The introduction of bedaquiline (BDQ) has reduced the reliance on ototoxic drugs (e.g., aminoglycosides) for drug-resistant TB (DR-TB). This has significantly reduced ototoxic symptoms, such as tinnitus and dizziness, which often precede irreversible hearing loss. However, aminoglycosides remain essential for some extensively drug-resistant individuals with TB (XDR-TB) who are resistant to BDQ. In South Africa, there is a lack of adequate awareness of the potential ototoxic effects of aminoglycosides. The increasing prevalence of XDR-TB has, therefore, intensified the need for comprehensive information counselling. We call for a proactive role for audiologists in providing early, structured information counselling for these individuals.
贝达喹啉（BDQ）的引入减少了耐多药结核病（DR-TB）治疗对耳毒性药物（如氨基糖苷类）的依赖。这显著减轻了耳鸣和头晕等耳毒性症状，而这些症状往往是不可逆听力损失的先兆。然而，对于一些对BDQ耐药的广泛耐药结核病（XDR-TB）患者，氨基糖苷类药物仍然必不可少。在南非，人们对氨基糖苷类药物潜在的耳毒性影响缺乏足够的认识。因此，XDR-TB患病率的上升加剧了提供全面信息咨询的必要性。我们呼吁听力学家发挥积极作用，为这些患者提供早期、系统化的信息咨询。
